Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and
dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms,
assessment of the reasons for add-on treatment with L-Dopa and dosing of pramipexole and
L-Dopa when given concomitantly.